Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Bordeaux
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in terms of disease control: local treatment of the main tumor and brain versus systemic treatment with chemotherapy and immunotherapy. We will analyze the impact of these 2 strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Consecutive patients managed at Bordeaux University Hospital
Non-small-cell lung cancer
Oligometastatic brain cancer (fewer than 5 lesions at diagnosis)
Patient over 18 years old
You may not be if
Oncogenic addiction EGFR, ALK, ROS1
Patient with concomitant cancer
Patient with prior treatment for lung cancer in the year preceding diagnosis at metastatic stage
